Breaking News

Dollar Tree Agrees to Buy Family Dollar for $74.50 a Share
Tweet TWEET

Factors Moving Markets- Research Report on Actavis, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Gilead Sciences Inc.

  Factors Moving Markets- Research Report on Actavis, Inc., AstraZeneca PLC,
     Bristol-Myers Squibb Company, Gilead Sciences Inc. and Novo Nordisk

PR Newswire

NEW YORK, March 1, 2013

NEW YORK, March 1, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Actavis,
Inc. (NYSE: ACT), AstraZeneca PLC (NYSE: AZN), Bristol-Myers Squibb Company
(NYSE: BMY), Gilead Sciences Inc. (NASDAQ: GILD) and Novo Nordisk A/S (NYSE:
NVO). Today's readers may access these reports free of charge - including full
price targets, industry analysis and analyst ratings - via the links below.

Actavis, Inc. Research Report

The US Food and Drug Administration (FDA) recently approved Actavis' generic
Suboxone for maintenance treatment of opioid dependence. According to IMS
Health Data, total sales for Actavis Suboxone reached $625 million for
full-year 2012, and it is expected to surge in revenues after the approval.
Drug dependence is a common problem in various regions, and Actavis' generic
Suboxone may possibly rake in a great market share in the global market.
Actavis reported net revenue increase of 13% to $1.75 billion during the
fourth quarter and 29% to $5.9 billion for full-year 2012. The Full Research
Report on Actavis, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/d9b4_ACT]

--

AstraZeneca PLC Research Report

Investors are looking forward to AstraZeneca's Capital Markets Day on March
21, 2013 when the company announces its new strategy amid the challenges
caused by global market conditions. AstraZeneca remains positive after
receiving high-level results from KODIAC-08, a 52-week-long safety trial for
Naloxegol versus usual care. The core PhaseIII programme is now completed, and
AstraZeneca is advancing Naloxegol for regulatory submission within the year.
Naloxegol is used for the treatment of opioid-pain-medicine-related
constipation, and is a product under the exclusive worldwide license agreement
between AstraZeneca and Nektar Therapeutics. The Full Research Report on
AstraZeneca PLC - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/8c20_AZN]

--

Bristol-Myers Squibb Company Research Report

The collaboration agreement between Bristol-Myers and Reckitt Benckiser allows
the former to easily penetrate Latin America through the distribution and
marketing of several over-the-counter medicines. Bristol-Myers will receive
$438 million from Reckitt Benckiser apart from royalties on product sales
during its collaboration term. Brazil and Mexico, both emerging markets, are
the primary segments where these several products will circulate. According to
an official press release from Bristol-Myers, the company's biopharma strategy
allows the company to focus on providing innovative medicines in areas of high
unmet medical need. The Full Research Report on Bristol-Myers Squibb Company -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/4a88_BMY ]

--

Gilead Sciences Inc. Research Report

Despite Gilead's leadership in HIV/AIDS treatments, the company's acquisition
of YM BioSciences Inc. is a foolproof reason for analysts and investors to be
bullish about the company. The company's long-term growth looks promising as
it continues to boost its portfolio with smart acquisitions. Gilead raked in
17.6% revenue growth to $2.59 billion during the fourth quarter. Analysts are
expecting Gilead to post better revenues as soon as it utilizes cancer
treatments that are reported to have a great market. The Full Research Report
on Gilead Sciences Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/5969_GILD]

--

Novo Nordisk A/S Research Report

Novo Nordisk, a global healthcare company with 90 years of innovation and
leadership in diabetes care, recently launched NovoSeven with pre-filled
syringe for fast bleeding control. NovoSeven is a support rapid treatment for
haemophilia patients with inhibitors. Novo Nordisk already received approvals
for NovoSeven from European Medicines Agency (EMA) and US Food and Drug
Administration (FDA). The company's Tresiba, a once-daily basal insulin, is
also ready for release in Japan. Analysts are expecting Novo Nordisk to
penetrate more markets in the coming quarters. The Full Research Report on
Novo Nordisk A/S - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/4e4f_NVO]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@investors-alliance.com
Main: +1-(480)-745-7826

SOURCE Investors-Alliance